Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Data Analysis Reinforces the Safety Profile of Levemir(R)
November 3rd, 2009
A meta-analysis of clinical data published in Diabetologia, the medical journal for the European Association for the Study of Diabetes (EASD), demonstrated that the Novo Nordisk long-acting insulin Levemir=AE (insulin detemir [rDNA origin] injection) was not associated with any increase in the incidence of cancer when compared to human insulin(1,2). The analysis conducted by Novo Nordisk assessed the relative risk of a cancer diagnosis during clinical treatment with Levemir=AE. It included approximately 9,000 patients (approximately 5,200 taking Levemir=AE) in 21 randomized controlled trials and compared the incidence of cancer in patients treated with Levemir=AE with...
Source: Cancer Weekly (2009-11-03)
|
